Company Encyclopedia
View More
name
Kiniksa Pharmaceuticals
KNSA.US
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024.
1.946 T
KNSA.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
A
BiotechnologyIndustry
Industry Ranking2/393
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE7.39%B
    • Profit Margin6.01%B
    • Gross Margin53.80%B
  • Growth ScoreA
    • Revenue YoY55.68%A
    • Net Profit YoY496.10%A
    • Total Assets YoY28.28%A
    • Net Assets YoY22.51%A
  • Cash ScoreA
    • Cash Flow Margin1664.83%B
    • OCF YoY55.68%A
  • Operating ScoreA
    • Turnover0.94A
  • Debt ScoreB
    • Gearing Ratio24.84%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Kiniksa COO Eben Tessari Reports Disposal of Common Shares

    Eben Tessari, COO of Kiniksa Pharmaceuticals, reported the disposal of common shares. The filing is available via EDGAR, the SEC's system. This AI-generated brief is for informational purposes and not financial advice. Kiniksa is responsible for the original content.

    Reuters·
    US
    KNSA
    +0.99%
    Reuters·
    US
    KNSA
    +0.99%

    Universal Beteiligungs und Servicegesellschaft mbH Makes New Investment in Kiniksa Pharmaceuticals International, plc $KNSA

    Universal Beteiligungs und Servicegesellschaft mbH has invested in Kiniksa Pharmaceuticals International, purchasing 9,140 shares valued at $253,000 in Q2. Other institutional investors have also acquired stakes. Insider sales include CAO Michael R. Megna and CEO Sanj K. Patel. Analysts have mixed ratings, with a moderate buy consensus and a $52 average price target. Kiniksa's stock opened at $42.49, with a market cap of $3.22 billion. Recent earnings missed estimates, but revenue increased by 61.2% year-over-year.

    Market Beat·
    US
    KNSA
    +0.99%
    Market Beat·
    US
    KNSA
    +0.99%

    COO Tessari Files To Sell 48,384 Of Kiniksa Pharmaceuticals Ltd [KNSA]

    COO Tessari Eben of Kiniksa Pharmaceuticals Ltd filed a Form 144 with the SEC to sell 48,384 restricted shares on November 26, 2025, through Charles Schwab & Co Inc, under a prearranged trading plan (10b5-1). The sale must occur within 90 days of filing.

    Reuters·
    US
    KNSA
    +0.99%
    Reuters·
    US
    KNSA
    +0.99%

    How Investors Are Reacting To Kiniksa Pharmaceuticals (KNSA) Raised Outlook Following Strong Arcalyst Sales

    Kiniksa Pharmaceuticals reported strong Q3 2025 earnings, driven by Arcalyst sales, and raised its full-year net sales outlook to $670-$675 million. Despite the positive outlook, reliance on Arcalyst poses risks if competitive or regulatory challenges arise. The company is forecasted to achieve $992 million in revenue by 2028, with a fair value estimate of $54.00 per share, indicating a 30% upside. Investors should consider the potential impact of changes in Arcalyst's market environment on Kiniksa's growth.

    Simplywall·
    US
    KNSA
    +0.99%
    Simplywall·
    US
    KNSA
    +0.99%

    Kiniksa Pharmaceuticals (KNSA) Receives a Buy from Jefferies

    Jefferies analyst Roger Song maintained a Buy rating on Kiniksa Pharmaceuticals with a price target of $58.00. Song, who covers the Healthcare sector, has an average return of -5.1% and a 37.50% success rate. The analyst consensus rating for Kiniksa Pharmaceuticals is Strong Buy with a $52.00 average price target.

    Tip Ranks·
    US
    KNSA
    +0.99%
    Tip Ranks·
    US
    KNSA
    +0.99%
    © 2025 Longbridge｜Disclaimer